Free CPD-accredited Diploma introduces learners to the science of how medicines work — and the profession responsible for making sure they don't cause harm
The WHO estimates that preventable medication errors and unsafe practices affect 1 in every 20 patients globally. These errors account for nearly 50% of all preventable harm in medical care, with over one-quarter of that harm considered severe or life-threatening. Behind every one of those statistics is a gap — in knowledge, in systems, and in the trained professionals needed to monitor drug safety at scale. The profession built to close that gap is called pharmacovigilance. Most people have never heard of it.
Alison has launched a new free, CPD-accredited Diploma — Diploma in Pharmacology and Pharmacovigilance — designed to change that. Developed with Cong Cao, a practising pharmacist, the course covers both the science of how drugs interact with the body and the practical skills of drug safety monitoring: identifying adverse reactions, understanding risk, reporting safety signals, and supporting better outcomes in real healthcare environments. It is accessible to beginners with no prior pharmacology background.
The Hidden Workforce Behind Safe Medicines
When the COVID-19 vaccines were rolled out at unprecedented speed, it was pharmacovigilance systems that detected the rare blood clot signals, flagged the myocarditis risk in younger males, and gave regulators the data to update guidance in real time. In countries with robust pharmacovigilance infrastructure, those signals were caught quickly. In countries without it, harmful patterns can persist undetected for months or years — and patients pay the price.
The pharmaceutical industry is expanding rapidly across Asia, Latin America, and sub-Saharan Africa, driven by political will to build domestic manufacturing capacity and reduce dependence on imported medicines. That expansion requires a pharmacovigilance workforce that doesn't yet exist at scale in many of those markets. The knowledge to monitor drug safety, report adverse events, and interpret clinical risk is in short supply precisely where it is needed most.
From "Why Doesn't This Medicine Work For Me?" to Understanding the Answer
The Diploma starts with the question most patients have asked at some point: why does the same medicine work differently from one person to the next — or cause harm in one person and not another? The answer lies in pharmacology: how drugs are absorbed, distributed, metabolised, and excreted, and how individual variation in those processes shapes both efficacy and risk. From that foundation, the course moves into pharmacovigilance — how drug safety is tracked, reported, and managed across real healthcare systems — equipping learners to recognise harmful reactions, avoid common prescribing errors, and communicate risk clearly to patients and colleagues.
The Diploma is relevant for healthcare workers, pharmacy assistants, clinical researchers, regulatory affairs professionals, and anyone working in pharmaceutical or public health settings who needs a stronger grounding in drug safety science.
Cong Cao, stated: "This course provides a comprehensive introduction to pharmacology and pharmacovigilance for anyone working in or interested in working in a healthcare setting. Developed for adult learners with a basic understanding of medicine, it covers how medicines work in the body, how they are monitored for safety after approval, and how errors and adverse reactions are identified and prevented. No prior pharmacy knowledge is assumed, and key terminology is explained throughout."
The Diploma is available now through any desktop browser or the Alison App on Android and iOS, with a free digital Diploma on completion.
To learn more or enrol, visit: https://alison.com/course/Diploma-in-pharmacology-and-pharmacovigilance
Ends
Media contact
For further information, contact the media team at [email protected].
About Alison
Alison is a global leader in free online learning and skills development. With over 50 million registered learners across 193 countries (as of October 2025), Alison empowers individuals, communities, and organisations to upskill quickly and effectively – at zero cost.
The Alison platform provides immediate access to over 6,000 free, CPD-accredited courses, covering essential areas such as Artificial Intelligence, Data Science, Cybersecurity, Digital Marketing, Project Management, Business Operations, Healthcare and Sustainability. Courses are created by a mix of independent experts and global leaders, including IBM, Stanford and Microsoft.
For organisations, Alison offers a Free Learning Management System (LMS) that enables unlimited learners to access thousands of courses with no upfront cost. A premium version with advanced analytics and customisation is also available. Alison's offering includes a full suite of assessments and psychometric tools, including a Workplace Personality Assessment, Mental Health & Wellbeing Assessment, English Language Proficiency Test, as well as Numerical, Verbal, and Abstract Reasoning tests.
To further support career development, learners also gain access to a Career Guide, a Resumé Builder, and the ability to study offline through the Alison App. The platform is also expanding its reach with multilingual versions, starting with complete Spanish, French, and Hindi offerings — reaffirming its mission to make education accessible to anyone, anywhere.
Founded in 2007, Alison pioneered the concept of free, large-scale online learning and is recognised as the world’s first MOOC (Massive Open Online Course) platform. Today, its mission continues: to break down barriers to learning, helping people gain skills, build confidence, and improve their lives — no matter where they live or what they earn.
